Literature DB >> 18181539

Studies on a novel doughnut-shaped minitablet for intraocular drug delivery.

Yahya E Choonara1, Viness Pillay, Trevor Carmichael, Michael P Danckwerts.   

Abstract

The objective of this study was to evaluate the effect of 2 independent formulation variables on the drug release from a novel doughnut-shaped minitablet (DSMT) in order to optimize formulations for intraocular drug delivery. Formulations were based on a 3(2) full-factorial design. The 2 independent variables were the concentration of Resomer (% wt/wt) and the type of Resomer grade (RG502, RG503, and RG504), respectively. The evaluated response was the drug release rate constant computed from a referenced marketed product and in vitro drug release data obtained at pH 7.4 in simulated vitreous humor. DSMT devices were prepared containing either of 2 model drugs, ganciclovir or foscarnet, using a Manesty F3 tableting press fitted with a novel central-rod, punch, and die setup. Dissolution data revealed biphasic drug release behavior with 55% to 60% drug released over 120 days. The inherent viscosity of the various Resomer grades and the concentration were significant to achieve optimum release rate constants. Using the resultant statistical relationships with the release rate constant as a response, the optimum formulation predicted for devices formulated with foscarnet was 70% wt/wt of Resomer RG504, while 92% wt/wt of Resomer RG503 was ideal for devices formulated with ganciclovir. The results of this study revealed that the full-factorial design was a suitable tool to predict an optimized formulation for prolonged intraocular drug delivery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18181539      PMCID: PMC2750704          DOI: 10.1208/pt0804118

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  13 in total

1.  Response surface methodology as a predictive tool for determining the effects of preparation conditions on the physicochemical properties of poly(isobutylcyanoacrylate) nanoparticles.

Authors:  P A McCarron; A D Woolfson; S M Keating
Journal:  Int J Pharm       Date:  1999-12-20       Impact factor: 5.875

2.  Design of experiments for capillary electrophoretic enantioresolution of salbutamol using dermatan sulfate.

Authors:  R Gotti; S Furlanetto; V Andrisano; V Cavrini; S Pinzauti
Journal:  J Chromatogr A       Date:  2000-04-14       Impact factor: 4.759

3.  Intravitreal sustained-release ganciclovir.

Authors:  T J Smith; P A Pearson; D L Blandford; J D Brown; K A Goins; J L Hollins; E T Schmeisser; P Glavinos; L B Baldwin; P Ashton
Journal:  Arch Ophthalmol       Date:  1992-02

4.  Optimisation of aciclovir poly(D,L-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study.

Authors:  C Martínez-Sancho; R Herrero-Vanrell; S Negro
Journal:  Int J Pharm       Date:  2004-04-01       Impact factor: 5.875

5.  Microspheres of biodegradable polymers as a drug-delivery system in the vitreous.

Authors:  T Moritera; Y Ogura; Y Honda; R Wada; S H Hyon; Y Ikada
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-05       Impact factor: 4.799

6.  Textural profiling and statistical optimization of crosslinked calcium-alginate-pectinate-cellulose acetophthalate gelisphere matrices.

Authors:  Viness Pillay; Michael P Danckwerts
Journal:  J Pharm Sci       Date:  2002-12       Impact factor: 3.534

7.  Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study.

Authors:  J Vandervoort; A Ludwig
Journal:  Int J Pharm       Date:  2002-05-15       Impact factor: 5.875

8.  Biodegradable scleral implant for intravitreal controlled release of ganciclovir.

Authors:  T Yasukawa; H Kimura; N Kunou; H Miyamoto; Y Honda; Y Ogura; Y Ikada
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-02       Impact factor: 3.117

9.  Poly (D,L-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives.

Authors:  C Martínez-Sancho; R Herrero-Vanrell; S Negro
Journal:  J Microencapsul       Date:  2003 Nov-Dec       Impact factor: 3.142

10.  Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device.

Authors:  G E Sanborn; R Anand; R E Torti; S D Nightingale; S X Cal; B Yates; P Ashton; T Smith
Journal:  Arch Ophthalmol       Date:  1992-02
View more
  1 in total

1.  Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time.

Authors:  Amany O Kamel; Gehanne A S Awad; Ahmed S Geneidi; Nahed D Mortada
Journal:  AAPS PharmSciTech       Date:  2009-12-01       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.